Sign inJoin waitlistJoin the waitlist

HL

Hugh Lin

Ophthalmology

Credentials: · · · ·

History

Stanford Health Care
2008–2009
Ophthalmology
Washington University/B-JH/SLCH Consortium
2005–2008
Preliminary Internal Medicine
Olive View/UCLA Medical Center
2004–2005
Boston University School of Medicine
2000–2004

Research

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised,…
The Lancet · 2022 · 670 citations
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised,…
The Lancet · 2022 · 396 citations
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2
Ophthalmology · 2024 · 192 citations

CW
Charles Wykoff
4 papers
JW
Jeffrey Willis
4 papers
AK
Arshad Khanani
3 papers
JH
Jeffrey Heier
3 papers
KC
Karl Csaky
3 papers
BS
Bala Swaminathan
2 papers
CB
Caroline Baumal
2 papers
JW
John Wells
2 papers
Kuldev Singh
2 papers
Rishi Singh
2 papers
AA
Anthony Adamis
1 paper
Anurag Shrivastava
1 paper